Coinfection and cross-reaction of dengue and COVID-19: a case series analysis.
Rev Soc Bras Med Trop
; 55: e02432022, 2022.
Article
in English
| MEDLINE | ID: covidwho-2270174
ABSTRACT
BACKGROUND:
The risk of possible cross-reactions between serological tests, together with the clinical similarities between dengue fever and COVID-19, can delay diagnosis and increase the risk of both COVID-19 transmission and worsening. The present study aimed to determine the possibility of cross-reactions among rapid serological tests based on clinical symptoms.METHODS:
Patients with COVID-19, confirmed by RT-PCR and clinical criteria for diagnosing dengue, were recruited consecutively between September 2020 and August 2021 and underwent rapid immunochromatographic diagnostic (RID) tests for AgNS1, IgM, and IgG. Patients who tested positive for acute-phase dengue IgM and AgNS1 underwent a follow-up test after 12-30 days for diagnostic confirmation.RESULTS:
A total of 43 patients were included, 38 of whom required hospital admission, and 8 received intensive care. Seven patients tested positive on the RID tests, comprising 2 NS1 positive (coinfection), one reactive for IgM and IgG (coinfection), three reactive for IgM not confirmed (false-positive), and one reactive for IgG due to previous infection. Two of the 3 patients with coinfection died. Fever, myalgia, headache, and cough were the most common clinical symptoms, while lymphopenia was the most prevalent laboratory finding.CONCLUSIONS:
Cross-reactivity was found in only three patients and coinfection in another three patients, two of whom died of severe COVID-19 manifestations.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Dengue
/
Coinfection
/
COVID-19
Type of study:
Cohort study
/
Diagnostic study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Rev Soc Bras Med Trop
Year:
2022
Document Type:
Article
Affiliation country:
0037-8682-0243-2022
Similar
MEDLINE
...
LILACS
LIS